Beam Therapeutics' Evans proposes $600K share sale
The notice lists the shares as obtained through a stock option exercise from the issuer, with cash payment.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Beam Therapeutics Inc. officer and director John M. Evans, who signed as John Martin Evans III, reported a proposed sale of 25,000 common shares with an aggregate market value of $599,595.00 through Morgan Stanley Smith Barney LLC, dated October 16, 2026. The notice lists the shares as acquired from the issuer through a stock option exercise for cash on October 16, 2026. It also reports that Evans sold 25,000 common shares on October 15, 2026, with an aggregate market value of $589,150.00.
Key Figures
Key Terms
Rule 144 regulatory
Stock Option Exercise financial
Aggregate market value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.